Antibody detailed product information

Code No. D186-3
Anti-Granulysin (Human) mAb
Price ¥52,800
Size 100 µL (1 mg/mL)
Availability (in Japan) 10 or more
（In Japan at 17:00, Apr 18, 2024 in JST）
Clonality Monoclonal
Clone RF10
Isotype
(Immunized Animal) 		Mouse IgG2aκ
Applications WB　1 µg/mL  
IP　5 µg/200 µL of cell extract from 5x106 cells  
FCM　5-10 µg/mL (final concentration)  
IC　2-5 µg/mL  
IH*　（PMID: 27421110 / 28027826）
Immunogen
(Antigen)		 full-length human Granulysin expressing plasmids
Reactivity [Gene ID]

Human[10578]
Storage buffer 1 mg/mL in PBS/50% glycerol, pH 7.2
Storage temp. -20°C
Conjugate Unlabeled
Manufacturer MBL
Alternative names GNLY
Background Granulysin is an antimicrobial protein expressed on cytotoxic T cells, natural killer (NK) cells and NKT cells. It has been shown that Granulysin contributes to the defence mechanisms against variety of mycobacterial infection and tumors. Granulysin has two molecular forms, 15-kDa precursor and 9-kDa effector form. There serum levels were significantly elevated during the acute viral infections and correlated with the NK cell and CTL activities in patients with sever immunodeficiency, indicate that serum Granulysin could be useful novel marker to evaluate the overall status of host cell immunity.
Related products D185-3 Anti-Granulysin (Human) mAb
D185-6 Anti-Granulysin (Human) mAb-Biotin
D184-3 Anti-Granulysin (Human) mAb
Product category Research area:Immunology Apoptosis
Data

Citations

Western Blotting

  1. Chung WH et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 14, 1343-50 (2008)(PMID:19029983)
  2. Hsiao YW et al. Granulysin expressed in a humanized mouse model induces apoptotic cell death and suppresses tumorigenicity. Oncotarget 8, 83495-83508 (2016)(PMID:29137359)

Flow Cytometry

  1. Merlo A et al. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol. 184, 5895-902 (2010)(PMID:20385879)

Immunocytochemistry

  1. Clayberger C et al. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol. 188, 6119-26 (2012)(PMID:22586033)
  2. Sekiguchi N et al. Elevated serum granulysin and its clinical relevance in mature NK-cell neoplasms. Int J Hematol. 96, 461-8 (2012)(PMID:22890551)
  3. Wei HM et al. Antimicrobial Properties of an Immunomodulator - 15 kDa Human Granulysin. PLoS One 11, e0156321 (2016)(PMID:27276051)

Immunohistochemistry

  1. Weinborn M et al. Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression. Int J Dermatol. 55, 1225-1233 (2016)(PMID:27421110)
  2. Second J et al. Clinicopathologic analysis of atypical hand, foot, and mouth disease in adult patients. J Am Acad Dermatol. 76, 722-729 (2017)(PMID:28027826)
  • The availability is based on the information in Japan at 17:00, Apr 18, 2024 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • Abbreviations for applications：
    WB: Western Blotting, IH: Immunohistochemistry, IC: Immunocytochemistry, IP: Immunoprecipitation
    FCM: Flow Cytometry, NT: Neutralization, IF: Immunofluorescence, RIP: RNP Immunoprecipitation
    ChIP: Chromatin Immunoprecipitation, CoIP: Co-Immunoprecipitation
    DB: Dot Blotting, NB: Northern Blotting, RNA FISH: RNA Fluorescence in situ hybridization
  • For applications and reactivity:
    *: The use is reported in a research article (Not tested by MBL). Please check the data sheet for detailed information.
    **: The use is reported from the licenser (Under evaluation or not tested by MBL).
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.
MBLCopyright (C)2015 Medical ＆ Biological Laboratories Co., Ltd. All Rights Reserve